Table 1.

Characteristics of the different anti-TNF agents.

	Infliximab	Etanercept	Adalimumab	Certolizumab pegol	Golimumab
Type	Monoclonal antibody against TNF-α	TNF soluble receptor	Monoclonal antibody against TNF-α	Monoclonal antibody against TNF-α	Monoclonal antibody against TNF-α
Composition	Chimeric antibody	Recombinant fusion protein	Recombinant monoclonal antibody	Monoclonal antibody	Monoclonal antibody
Origin	Human and murine	Human	Human	Human	Human
Mechanism of action	Binding to soluble and cell-bound TNF-α	Binding to soluble TNF-α and TNF-β	Binding to soluble and cell-bound TNF-α	Binding to soluble and cell-bound TNF-α	Binding to soluble and cell-bound TNF-α
Dose	3–5 mg/kg at weeks 0, 2, and 6; then, every 4–8 weeks	25–50 mg once or twice a week	40 mg every other week	400 mg every other week (maintenance every 4 weeks can be considered)	50 mg once monthly
Administration route	Intravenous	Subcutaneous	Subcutaneous	Subcutaneous	Subcutaneous